Literature DB >> 30511436

Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.

Myeong Gyu Kim1, Arim Kwak2, Boyoon Choi3, Eunhee Ji4, Jung Mi Oh3, Kyungim Kim2.   

Abstract

This meta-analysis was conducted to derive an integrated conclusion about the influence of glutathione S-transferase (GST) genetic polymorphisms on busulfan pharmacokinetic (PK) parameters and veno-occlusive disease (VOD). Studies which analysed the effect of GST genetic polymorphisms on area under the curve (AUC), clearance (CL) or VOD were searched for and selected. A pooled analysis was conducted using Comprehensive Meta-Analysis programme. Nineteen studies were included in this meta-analysis. GSTA1*B and GSTM1 null genotypes significantly decreased CLIV of busulfan (standardized difference in means (SDM) = -1.103; P = 0.019 and SDM = -0.418; P = 0.002, respectively). GSTA1*B significantly increased AUCIV of busulfan (SDM = 0.832; P = 0.046), whereas GSTM1 did not (SDM = 0.155; P = 0.478). The PK parameters of oral busulfan did not differ according to GST genotype. GSTA1, GSTM1 and GSTP1 were not significantly associated with VOD occurrence. GSTA1 and GSTM1 genotypes affected CLIV of busulfan, but only GSTA1 affected AUCIV . There was no significant difference in the PK parameters of oral busulfan (CLPO and AUCPO ) and VOD when only GST genotypes were considered.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Keywords:  busulfan; genetic polymorphisms; glutathione S-transferase; pharmacokinetics; veno-occlusive disease

Mesh:

Substances:

Year:  2018        PMID: 30511436     DOI: 10.1111/bcpt.13185

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

1.  The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study.

Authors:  Xiaohuan Du; Chenrong Huang; Ling Xue; Zheng Jiao; Min Zhu; Jie Li; Jun Lu; Peifang Xiao; Xuemei Zhou; Chenmei Mao; Zengyan Zhu; Ji Dong; Xiaoxue Liu; Zhiyao Chen; Shichao Zhang; Yiduo Ding; Shaoyan Hu; Liyan Miao
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.

Authors:  Yidan Sun; Jingjing Huang; Chenxia Hao; Ziwei Li; Wu Liang; Weixia Zhang; Bing Chen; Wanhua Yang; Jiong Hu
Journal:  Cancer Chemother Pharmacol       Date:  2019-12-13       Impact factor: 3.333

Review 3.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26

4.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.

Authors:  Claire Seydoux; Raphael Battegay; Joerg Halter; Dominik Heim; Katharina M Rentsch; Jakob R Passweg; Michael Medinger
Journal:  Bone Marrow Transplant       Date:  2022-03-31       Impact factor: 5.174

5.  Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?

Authors:  Abdullah Alsultan; Ahmed A Albassam; Abdullah Alturki; Abdulrahman Alsultan; Mohammed Essa; Bader Almuzzaini; Salman Alfadhel
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

6.  Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations.

Authors:  Jinjie Yuan; Ning Sun; Xinying Feng; Huan He; Dong Mei; Guanghua Zhu; Libo Zhao
Journal:  Pharmgenomics Pers Med       Date:  2021-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.